Severe phenytoin intoxication in patients with hypoalbuminaemia;Ernstige fenytoïne-intoxicatie bij patiënten met hypoalbuminemie

Nederlands Tijdschrift voor Geneeskunde

Volumn 151, Issue 2, 2007, Pages 138-141

  Kemper, E M ^a   Van Kan, H J M ^a   Speelman, P ^b   De Gans, K ^b   Beijnen, J H ^c   Schellens, J H M ^c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PHENYTOIN;

ADULT; ANAMNESIS; BRAIN VENTRICLE PERITONEUM SHUNT; CASE REPORT; CLINICAL FEATURE; COMA; DIABETIC KETOACIDOSIS; DISORIENTATION; DROWSINESS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG WITHDRAWAL; EPILEPTIC STATE; FEMALE; HALLUCINATION; HUMAN; HYDROCEPHALUS; HYPOALBUMINEMIA; MALE; MYOCLONUS; REVIEW; RISK ASSESSMENT; SEIZURE; SPINA BIFIDA; URINARY TRACT INFECTION;

ADULT; ANTICONVULSANTS; BLOOD PROTEINS; DRUG MONITORING; FATAL OUTCOME; FEMALE; HUMANS; HYPOALBUMINEMIA; MALE; MIDDLE AGED; PHENYTOIN;

EID: 33846632425     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (12)

1. Lund M, Jorgensen RS, Kuehl V. Serum diphenylhydantoin (phenytoin) in ambulant patients with epilepsy. Epilepsia. 1964;23:51-8.
2. Lund L. Anticonvulsant effect of diphenylhydantoin relative to plasma levels. A prospective three-year study in ambulant patients with generalized epileptic seizures. Arch Neurol. 1974;31:289-94.
3. Booker HE, Darcey B. Serum concentrations of free diphenylhydantoin and their relationship to clinical intoxication. Epilepsia. 1973;14:177-84.
4. Liponi DF, Winter ME, Tozer TN. Renal function and therapeutic concentrations of phenytoin. Neurology. 1984;34:395-7.
5. Peterson GM, McLean S, Aldous S, von Witt RJ, Millingen KS. Plasma protein binding of phenytoin in 100 epileptic patients. Br J Clin Pharmacol. 1982;14:298-300.
6. Iwamoto T, Kagawa Y, Naito Y, Kuzuhara S, Okuda M. Clinical evaluation of plasma free phenytoin measurement and factors influencing its protein binding. Biopharm Drug Dispos. 2006;27:77-84.
7. Dasgupta A, Dennen DA, Dean R, McLawhon RW. Prediction of free phenytoin levels based on [total phenytoin]/[albumin] ratios. Potential errors with hypoalbuminemia. Am J Clin Pathol. 1991;95:253-6.
8. Winter ME, Tozer TN. Phenytoin. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics, principles of therapeutic drug monitoring. 3rd ed. Vancouver: Lippincott; 1992. p. 1-30.
9. Kilpatrick CJ, Wanwimolruk S, Wing LMH. Plasma concentrations of unbound phenytoin in the management of epilepsy. Br J Clin Pharmacol. 1984;17:539-46.
10. Banh HL, Burton ME, Sperling MR. Interpatient and intrapatient variability in phenytoin protein binding. Ther Drug Monit. 2002;24:379-85.
11. Nation RL, Evans AM, Milne RW. Pharmacokinetic drug interactions with phenytoin (Part I). Clin Pharmacokinet. 1990;18:37-60.
12. Mamiya K, Yukawa E, Matsumoto T, Aita C, Goto S. Synergistic effect of valproate coadministration and hypoalbuminemia on the serum-free phenytoin concentration in patients with severe motor and intellectual disabilities. Clin Neuropharmacol. 2002;25:230-3.